Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tibetan medicine regimen 1 is a multi-component herbal treatment protocol developed by the Tibetan Hospital Mentsee Khang of the Tibet Autonomous Region for the management of asymptomatic and mild COVID-19 (Omicron variant). The regimen is a combination of three traditional Tibetan formulations: **Norbu 7** (Nuobu-Qi-Wei-San), **Shiwei Longdan Hua San** (Ten-ingredient Gentian Powder), and **Ershiwuwei Feibing Wan** (Twenty-five-ingredient Lung Disease Pill). These formulations are derived from classical Tibetan medical texts and are intended to clear heat, detoxify the body, and support respiratory function. Norbu 7 is typically used as a foundational clearing medicine, while the other components target specific symptoms associated with lung heat and inflammation. The regimen was evaluated in a prospective clinical study (ChiCTR2200063072) to assess its impact on viral shedding time, clinical efficacy, and safety in patients during the Omicron outbreak in Tibet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tibetan medicine regimen 1.